Home > Rheumatology > Upadacitinib shows benefit in psoriatic arthritis, higher dose bests adalimumab

Upadacitinib shows benefit in psoriatic arthritis, higher dose bests adalimumab


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters Health - 31/03/2021 - In patients with active psoriatic arthritis, daily oral upadacitinib produces significantly more improvement than placebo, but only recipients of the 30 mg dose experienced a significantly better outcome than with standard treatment with adalimumab, according to results from the SELECT-PsA 1 study. Success was measured by a decrease of at least 20% in the number of tender and swollen joints and an improvement of at least 20% on three of five domains in an American College of Rheumatology Scale after 12 weeks of therapy. By that metric the treatment success rate was 36.2% with placebo, 65.0% with adalimumab, 70.6% with 15 mg of upadacitinib daily and 78.5% with 30 mg daily. Only the 30 mg dose was superior to adalimumab. When it came to improvements of at least 70%, the rates at 12 weeks were 2.4%, 13.8%, 15.6% and 25.3%, respectively. The adverse-event rates, assessed through week 24, were similar in the four groups, but h...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on